Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

Sponsor
Beijing Chest Hospital
Study ID
NCT03651219
Phase
PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib Mmesylate tablets 250mg/d, po, there's totally 4-6 cycles(21days per cycle)
  • Irinotecan — DRUG
    Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)

Study Details

The aim of the study is to evaluate the safety and efficacy of apatinib mesylate tablets and chemotherapy drug Irinotecan in treatment of recurrent SCLC stage IIIB\&IV patients. It is a randomized controlled clinical trial.

Key Dates

Start date
Sep 8, 2018
Status verified
Aug 2018
Primary completion
Aug 8, 2019
Completion
Aug 8, 2020

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: experimental group
    Patients use Apatinib Mesylate tablets combined with Irinotecan.
  • Active Comparator: controlled group
    Patients use Irinotecan

Primary Outcome Measure

duration of treatment [ Time Frame: two years ]

Central Contacts

Related Studies